Navigation Links
Hospira Submits 510(k) Application to FDA for Symbiq™ Infusion System Modifications
Date:4/4/2011

LAKE FOREST, Ill., April 4, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), a leading provider of clinical information and medication delivery technologies, today announced that the company has submitted a 510(k) application with the U.S. Food and Drug Administration (FDA) for modifications to the Symbiq™ infusion system. The submission is one of the first developed to align with the recent FDA draft guidance for 510(k) infusion pump clearances.

"With this submission complete, we are on track to meet our commitments for resuming new customer shipments of Symbiq infusion pumps and advancing the continuous evolution of one of the most innovative infusion platforms in the hospital today," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "As one of the first companies to file an application under the draft FDA guidance for infusion pumps, we are looking forward to continuing to work with the Agency through this new and innovative regulatory process."

The 510(k) submission to FDA for clearance of the Symbiq infusion system version 3.11 identifies modifications Hospira has made to further enhance the reliability of the infusion pump.  In 2010, Hospira voluntarily placed shipments of the Symbiq pump on hold for customers, while the company finalized the proposed product upgrades. Hospira regularly communicates with current Symbiq customers regarding the status of the system modifications, and plans to upgrade all of the Symbiq infusion pumps currently in use once the FDA provides clearance.  Hospira submitted the 510(k) application to the FDA on March 31, 2011.

Hospira is working closely with the FDA to ensure that the Symbiq submission follows all guidelines of the new 510(k) draft guidance for infusion pumps. The timeframe for FDA clearance of the Symbiq upgrade cannot be determined. However, Hospira has dedicated the resources necessary to resume new shipments of the Symbiq infusion system as soon as the 510(k) is cleared.

For more information about the FDA draft guidance for 510(k) infusion pump submissions, visit: Guidance for Industry and FDA Staff - Total Product Life Cycle: Infusion Pump - Premarket Notification [510(k)] Submissions (issued April 23, 2010).

About the Symbiq Infusion System

The Symbiq infusion system is a technologically advanced infusion device with several clinician-friendly features incorporated to help improve workflow and decrease medication errors. With Hospira MedNet™ safety software built into the device, Symbiq was the first general infusion system designed to provide additional medication-error protection by requiring users to select a drug library entry from the safety software for all drug delivery programs. Due to its highly sophisticated technology, Symbiq is one of the first devices to achieve I.V. clinical integration of infusion pumps with electronic health record systems, which can help decrease the number of steps and time required to program the infusion pump.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness™. As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. The company is headquartered in Lake Forest, Ill., and has approximately 14,000 employees. Learn more at http://www.hospira.com.

Private Securities Litigation Reform Act of 1995 -- A Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the submission of the 501(k) application to the U.S. Food and Drug Administration (FDA) for the modified Symbiq infusion system. Hospira cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, regulatory, legal, technological and other factors that may affect Hospira's operations and may cause actual results to be materially different from expectations include the risks, uncertainties and factors discussed under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Hospira's latest Annual Report on Form 10-K filed with the Securities and Exchange Commission, which are incorporated by reference. Hospira undertakes no obligation to release publicly any revisions to forward-looking statements as the result of subsequent events or developments.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Launches Enhanced TheraDoc™ Clinical Surveillance System to Support Patient Safety and Help Improve Care
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. Hospira Announces U.S. Approval of Generic Docetaxel
4. Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
5. Hospira MedNet™ Portal Safety Software Benchmarking System Debuts at HIMSS
6. Hospira to Present at Upcoming Investor Conferences
7. Hospira Announces FDA Approval of Topotecan Injection
8. Hospira Reports Fourth-Quarter and Full-Year 2010 Results
9. Hospira to Host Conference Call for Fourth-Quarter 2010 Results and 2011 Projections
10. Hospira Launches Piperacillin and Tazobactam for Injection in the United States
11. Hospira Announces New Contracts in Effect with Novation for Infusion Pumps, Solutions and Equipment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... DUBLIN , Feb. 22, 2017  Allergan ... is proud to be a Gold sponsor of ... National Educating America Tour." This tour commemorates AFA,s15 ... availability of services and programs. The tour will ... free memory screenings and displays of the AFA ...
(Date:2/22/2017)... According to a new market research report "Process ... and Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO ... market is poised to reach USD 3.30 Billion by 2021 from USD ... 2021. Continue Reading ... ...
(Date:2/22/2017)... 22, 2017 The intersection ... and more prevalent today resulting in identifying and ... as well as other botanicals for discovering the ... marijuana therapies and their applications. Cannabis companies are ... designed to bring the new therapies to the ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... Patient Safety, patient advocates stress that the patient context (age, illness and life ... as reasons to mitigate their occurrence. In addition, all too often, ...
(Date:2/22/2017)... CALIFORNIA (PRWEB) , ... February 22, 2017 , ... ... the pipeline and the number of African American/Black students who want to become ... residents to pursue their careers as physicians in the Oakland/San Francisco Northern California, ...
(Date:2/21/2017)... ... February 21, 2017 , ... Tripp Lite, a world-leading ... extension cords that meet the most current standards. , The adoption by the ... National Fire Protection Association (NFPA) 101 – Life Safety Code (LSC) and NFPA ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, ... to the American Society of Plastic Surgeons. Some patients want to make a change ... their nose and improve their breathing ability. The team at usrhinoplasty.org is ...
(Date:2/21/2017)... ... February 21, 2017 , ... Support of value-based care models requires collaboration ... of data across industry solutions, Fogo Data Centers announces the launch of the Fogo ... healthy community is one in which all systems work well, work together, and work ...
Breaking Medicine News(10 mins):